Granted Patent B2

US 12,214,033 · App. 17/811,059 · Granted Feb 4, 2025

Inventors: Jana Barbero Calzado (Vienna, AT); Mario Nebenführ (Vienna, AT); Robert Schlegl (Siegenfield, AT); Michael Weber (Vienna, AT); Jürgen Heindl-Wruss (Vienna, AT)

Assignee: Valneva SE

A61K39/12A61K39/39A61P31/14C07K14/18C07K14/1825C12N7/00C12N7/02C12N7/06A61K2039/5252A61K2039/5254A61K2039/5258A61K2039/55505C12N2770/24134C12N2770/24151C12N2770/24163Y02A50/30

Abstract

Claims (24)

1. A method for separating infectious virus particles from non-infectious virus particles comprising precipitating the non-infectious virus particles with protamine, wherein the virus particles are selected from the group consisting of Paramyxoviridae, Orthomyxoviridae, Flaviviridae, Filoviridae, Arenaviridae, Rhabdoviridae, Togaviridae and Coronaviridae, and wherein the virus particles are not Zika virus particles.

2. The method according to claim 1 , wherein said protamine precipitation also facilitates the separation of infectious virus particles from host cell proteins and/or low molecular weight materials.

3. A method for purifying infectious virus particles, comprising the steps of

i) providing a crude harvest (a) comprising infectious virus particles, non-infectious virus particles, and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;

ii) contacting said crude harvest (a) with an agent comprising protamine to obtain a virus preparation (b) comprising infectious virus particles, wherein the enrichment of infectious virus particles in the virus preparation (b) relative to total virus particles in the crude harvest (a) is in the range of at least 50% to 95%,

wherein the virus particles are selected from the group consisting of Paramyxoviridae, Orthomyxoviridae, Flaviviridae, Filoviridae, Arenaviridae, Rhabdoviridae, Togaviridae and Coronaviridae, and wherein the virus particles are not Zika virus particles.

4. The method according to claim 3 , wherein said virus preparation (b) is further purified by one or more size exclusion methods selected from

i) sucrose density gradient centrifugation,

ii) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the pores comprise a molecular weight cut-off that excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cut-off of the pores can enter the ligand-activated core, and

iii) size exclusion chromatography;

to obtain a final virus preparation (c) comprising the infectious virus particles, less than 100 ng/ml residual host cell DNA, less than 1 μg/mL residual host cell protein, and less than 1 μg/mL virus particle aggregates.

5. The method according to claim 4 , wherein the final virus preparation (c) comprises less than 10 ng/mL residual host cell DNA and less than 100 ng/ml residual host cell protein.

6. The method according to claim 3 , wherein said crude harvest (a) is subjected to one or more pre-purification step(s) prior to step ii), wherein the one or more pre-purification step(s) comprise

a) filtration using a filter having a pore size equal to or less than 0.2 μm,

b) digestion of host cell genomic DNA by enzymatic treatment, and

c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 100 kDa.

7. The method according to claim 3 , wherein the concentration of protamine is between 0.5 mg/mL and 3 mg/mL.

8. The method according to claim 4 , wherein the infectious virus particles in said final virus preparation (c) are enriched by at least 50% to 95% relative to total virus particles in crude harvest (a).

9. The method according to claim 4 , wherein said virus preparation (c) comprises less than 10% impurities.

10. The method according to claim 3 , wherein said infectious virus particles are propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero-αHis cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, an MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.

11. The method according to claim 3 , wherein said infectious virus particles are selected from the group consisting of a live virus, an attenuated live virus, a chimeric virus, a modified live virus, and a recombinant live virus.

12. The method according to claim 4 , further comprising a step iv) comprising inactivating the virus preparation (c).

13. The method according to claim 12 , wherein said inactivating step iv) is performed using formaldehyde.

14. The method according to claim 3 , where said protamine is selected from the group comprising a protamine salt, a protamine sulphate, and a recombinant protamine sulphate.

Assignments (5)

Priority Claims (5)

Continuity (3)

References Cited (111)